Director Alex G. Howarth filed an initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing no securities held in Altimmune, Inc. as of the November 2, 2026 triggering event.

Key Highlights

  • Reporting person: Alex G. Howarth, listed as a Director of Altimmune, Inc. (NASDAQ:ALT).
  • Triggering event date: November 2, 2026, the date requiring the initial beneficial ownership statement.
  • No securities held: Both Table I (non-derivative securities) and Table II (derivative securities) are blank; the filing states "No securities are beneficially owned."
  • Filing date: The statement was signed and filed on November 4, 2026, by Gregory Weaver as Attorney-in-Fact.
  • Individual filing: The form was filed by one reporting person acting alone, not as part of a group.

Alex G. Howarth's Initial Ownership Disclosure at Altimmune

Altimmune, Inc., traded on NASDAQ under the ticker ALT, received an initial statement of beneficial ownership from newly reported director Alex G. Howarth. The filing, submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934, is required when an individual first becomes subject to reporting obligations as an officer, director, or significant shareholder of a public company. Howarth's address is listed as 350 Mount Kemble Avenue, Suite 1001, Morristown, New Jersey 07960.

According to the filing, Howarth holds no securities in Altimmune, either directly or indirectly. Table I, which covers non-derivative securities such as common stock, contains no entries. Table II, covering derivative securities such as options, warrants, or convertible instruments, is likewise empty. The filing explicitly notes: "No securities are beneficially owned." The statement was executed by Gregory Weaver, acting as Attorney-in-Fact, and signed on November 4, 2026.

Altimmune is a clinical-stage biopharmaceutical company. The initial ownership disclosure represents Howarth's starting baseline under Section 16 reporting requirements. Any subsequent acquisitions or dispositions of Altimmune securities by Howarth would trigger additional reporting obligations under SEC rules.

What Was Disclosed

The filing establishes that director Alex G. Howarth held no beneficial ownership of Altimmune, Inc. securities, in either non-derivative or derivative form, as of November 2, 2026. The statement was submitted on November 4, 2026, signed by Gregory Weaver as Attorney-in-Fact.